
Opinion|Videos|January 17, 2025
Overview and Benefits of Port Delivery System with Ranibizumab
Panelists discuss how the port delivery system (PDS) with ranibizumab represents a paradigm shift in neovascular AMD treatment by utilizing a surgically implanted refillable device that provides continuous medication delivery for 6 months, offering patients a preferred alternative to frequent intravitreal injections while ensuring consistent therapeutic levels.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Can you provide an overview of the port delivery system with ranibizumab approved for treating neovascular AMD?
- How does the device function?
- What are the benefits of using the port delivery system with ranibizumab?
- Certainty of 6 months of continuous anti-VEGF delivery
- Patients in clinical trials prefer PDS over intravitreal injections
Newsletter
Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Modern Retina
1
From AI to injury patterns: Insights from emerging ophthalmic research
2
FLORetina 2025: Reframing retinal disease through the lens of choroidal health
3
FLORetina 2025: Antithrombotic use examined in wet AMD submacular hemorrhage
4
FLORetina 2025: Remotely managing patients with neovascular age-related macular degeneration
5












































